Reviews on
Prostate Cancer


Volume 7 Number 5
May 2019


Home > Disciplines > Publications > Reviews on Prostate Cancer > Volume 7, Year 2019 > Number 5, May



CONTENTS


CLASSIFICATION
DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
ETIOLOGY, PATHOGENESIS, PATHOLOGY
FOLLOW-UP, QUALITY OF LIFE
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT



CLASSIFICATION

.

Paner GP, Gandhi J, Choy B, Amin MB.
Essential Updates in Grading, Morphotyping, Reporting, and Staging of Prostate Carcinoma for General Surgical Pathologists.
Arch Pathol Lab Med. 2019 Mar 13. doi: 10.5858/arpa.2018-0334-RA. [Epub ahead of print]
Source | Full text | Similar articles



DIAGNOSIS

.

Barakzai MA.
Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review
Asian Pac J Cancer Prev. 2019 Mar 26;20(3):661-666.
Source | Full text | Similar articles



.

Ekmekcioglu O, Busstra M, Klass ND, Verzijlbergen F.
Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.
J Nucl Med. 2019 Mar 8. pii: jnumed.118.222885. doi: 10.2967/jnumed.118.222885. [Epub ahead of print]
Source | Full text | Similar articles



.

Emberton M.
To see or not to see - what renders prostate cancer visible?
Nat Rev Urol. 2019 Mar 13. doi: 10.1038/s41585-019-0167-5. [Epub ahead of print]
Source | Full text | Similar articles
Comment on: Houlahan KE et al., Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
Eur Urol. 2019 Jan 24. pii: S0302-2838(18)31044-3. doi: 10.1016/j.eururo.2018.12.036. [Epub ahead of print].
Source / Full text



.

Galetti TP.
Is digital rectal examination still useful in prostate cancer diagnosis? YES!
Urologia. 2019 Feb;86(1):34. doi: 10.1177/0391560319834463.
Source | Full text | Similar articles



.

Lebastchi AH, Pinto PA.
The role of multiparametric MRI in biopsy-naive prostate cancer.
Nat Rev Urol. 2019 Mar 26. doi: 10.1038/s41585-019-0173-7. [Epub ahead of print]
Source | Full text | Similar articles



.

Miles B, Ittmann M, Wheeler T, Sayeeduddin M, Cubilla A, Rowley D, Bu P, Ding Y, Gao Y, Lee M, Ayala GE.
Moving Beyond Gleason Scoring.
Arch Pathol Lab Med. 2019 Mar 13. doi: 10.5858/arpa.2018-0242-RA. [Epub ahead of print]
Source | Full text | Similar articles



.

Sackett J, Choyke PL, Turkbey B.
Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better?
AJR Am J Roentgenol. 2019 Mar 19:1-9. doi: 10.2214/AJR.19.21178. [Epub ahead of print]
Source | Full text | Similar articles



.

Tan N, Bavadian N, Calais J, Oyoyo U, Kim J, Turkbey IB, Mena E, Davenport MS.
Imaging of PSMA-targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence After Definitive Therapy: A Systematic Review and Meta-analysis.
J Urol. 2019 Feb 25:101097JU0000000000000198. doi: 10.1097/JU.0000000000000198. [Epub ahead of print]
Source | Abstract | Similar articles



.

Totaro A.
Is digital rectal examination still useful in prostate cancer diagnosis? NO!
Urologia. 2019 Feb;86(1):32-33. doi: 10.1177/0391560319834462.
Source | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

Kaiser A, Haskins C, Siddiqui MM, Hussain A, D'Adamo C.
The evolving role of diet in prostate cancer risk and progression.
Curr Opin Oncol. 2019 Mar 15. doi: 10.1097/CCO.0000000000000519. [Epub ahead of print]
Source | Abstract | Similar articles



ETIOLOGY, PATHOGENESIS, PATHOLOGY

.

Sowder ME, Johnson RW.
Bone as a Preferential Site for Metastasis.
JBMR Plus. 2019 Jan 15;3(3):e10126. doi: 10.1002/jbm4.10126. eCollection 2019 Mar.
Source | Full text | Similar articles



.

Özdemir BC, Dotto GP.
Sex Hormones and Anticancer Immunity.
Clin Cancer Res. 2019 Mar 19. doi: 10.1158/1078-0432.CCR-19-0137. [Epub ahead of print]
Source | Full text | Similar articles



FOLLOW-UP, QUALITY OF LIFE

.

Catton CN, Shultz DB.
Should we expand the carbon ion footprint of prostate cancer?
Lancet Oncol. 2019 Mar 15. pii: S1470-2045(19)30094-4. doi: 10.1016/S1470-2045(19)30094-4. [Epub ahead of print]
Source | Full text | Similar articles
Comment on:
Mohamad O et al., Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study. Lancet Oncol. 2019 Mar 15. doi: 10.1016/S1470-2045(18)30931-8. [Epub ahead of print].
Source / Full text



INTEGRATIVE MEDICINE

.

Wu SY, Fang SC, Shih HJ, Wen YC, Shao YJ.
Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy.
Eur J Cancer. 2019 Feb 28. pii: S0959-8049(19)30047-4. doi: 10.1016/j.ejca.2018.11.032. [Epub ahead of print]
Source | Full text | Similar articles



OVERALL MANAGEMENT

.

Calzone KA et al., PDQ Cancer Genetics Editorial Board.
Genetics of Prostate Cancer (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2019 Mar 22.
Source | Book | Similar articles



.

Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As NJ, Lo SS, Moghanaki D, Loblaw A, Siva S.
Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
Curr Oncol Rep. 2019 Mar 27;21(5):43. doi: 10.1007/s11912-019-0791-5.
Source | Full text | Similar articles



.

Miller Croswell J et al., PDQ Screening and Prevention Editorial Board.
Prostate Cancer Screening (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2019 Mar 22.
Source | Book | Similar articles



.

Miller Croswell J et al., PDQ Screening and Prevention Editorial Board.
Prostate Cancer Prevention (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2019 Mar 1.
Source | Book | Similar articles



.

Muggia FM, et al., PDQ Adult Treatment Editorial Board.
Prostate Cancer Treatment (PDQ®): Patient Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2019 Feb 28.
Source | Book | Similar articles



PROGNOSIS

.

Lu TC, Collins L, Cohen P, Jay A, Campbell JM, O'Callaghan M.
Prognostic Differences in ISUP Grade Group 4: a Systematic Review and Meta-Analysis.
Pathol Oncol Res. 2019 Mar 14. doi: 10.1007/s12253-019-00632-1. [Epub ahead of print]
Source | Full text | Similar articles



TREATMENT

.

Livi L, Detti B, Francolini G, Terziani F, Triggiani L, D'Angelillo RM, Ingrosso G.
Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence.
Tumori. 2019 Mar 25:300891619839282. doi: 10.1177/0300891619839282. [Epub ahead of print]
Source | Full text | Similar articles



.

Pellizzon ACA.
Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet.
Int Braz J Urol. 2019 Jan-Feb;45(1):5-9. doi: 10.1590/S1677-5538.IBJU.2018.0734. Epub 2019 Jan 23.
Source | Full text | Similar articles



.

Roviello G, Generali D.
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.
Clin Genitourin Cancer. 2019 Feb 6. pii: S1558-7673(18)30797-3. doi: 10.1016/j.clgc.2019.01.020. [Epub ahead of print]
Source | Full text | Similar articles



.

Sternberg CN.
Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
Future Oncol. 2019 Mar 8. doi: 10.2217/fon-2018-0940. [Epub ahead of print]
Source | Full text | Similar articles



bottom